Capital Advisors Inc. OK Lowers Holdings in Pfizer Inc. $PFE

Key Points

• Capital Advisors Inc. OK decreased its holdings in Pfizer Inc. by 1.3%, owning 1,394,427 shares worth $33.8 million after selling 19,045 shares in the second quarter.
• Several research firms have adjusted their price targets for Pfizer, with Citigroup raising it to $26.00 while Morgan Stanley increased theirs to $33.00, indicating a mixed outlook among analysts.
• Pfizer reported a quarterly earnings per share (EPS) of $0.78, surpassing analysts' expectations, with a revenue of $14.65 billion reflecting a 10.3% year-over-year increase.

Capital Advisors Inc. OK trimmed its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 1.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,394,427 shares of the biopharmaceutical company's stock after selling 19,045 shares during the quarter. Capital Advisors Inc. OK's holdings in Pfizer were worth $33,801,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in PFE. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the first quarter valued at $27,000. North Capital Inc. purchased a new stake in shares of Pfizer during the 1st quarter worth about $28,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the 1st quarter worth about $28,000. Horizon Financial Services LLC purchased a new stake in shares of Pfizer during the 1st quarter worth about $35,000. Finally, WPG Advisers LLC purchased a new stake in shares of Pfizer during the 1st quarter worth about $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on PFE. Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Wall Street Zen downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Weiss Ratings restated a "hold (c-)" rating on shares of Pfizer in a research report on Saturday, September 27th. Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Finally, Bank of America upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research report on Friday. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $28.41.

Pfizer Stock Up 1.1%

PFE stock opened at $27.37 on Monday. The company has a market cap of $155.59 billion, a price-to-earnings ratio of 14.56, a PEG ratio of 0.88 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The firm has a 50-day moving average of $24.67 and a two-hundred day moving average of $24.12.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.